® (cabozantinib) compared with sunitinib, the current preferred therapy according to U.S. cancer treatment guidelines,
1 in patients with metastatic papillary renal cell carcinoma (PRCC), a form of kidney cancer. The data from the S1500 trial (also called “PAPMET”), which was designed and managed by SWOG Cancer Research Network, will be presented on Saturday, February 13
th during the Oral Abstract Session: Renal Cell Cancer at 10:00 – 11:15 a.m. PT at the 2021 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU), which is being held virtually, February 11-13, 2021. The findings will be simultaneously published in
The Lancet.
“This is the first randomized trial specific to metastatic papillary renal cell carcinoma to show a clinically and statistically significant benefit with a targeted therapy, CABOMETYX, over an existing standard of care,” said Dr. Sumanta Pal, Clinical Professor and Co-Director of the Kidney Cancer Program, City of H
Press release content from Business Wire. The AP news staff was not involved in its creation.
Exelixis Announces Positive Findings at ASCO GU for CABOMETYX® (cabozantinib) in Patients with Brain Metastases from Renal Cell Carcinoma
February 8, 2021 GMT
ALAMEDA, Calif. (BUSINESS WIRE) Feb 8, 2021
Exelixis, Inc. (NASDAQ: EXEL) today announced results from a retrospective analysis evaluating CABOMETYX ® (cabozantinib) activity in brain metastases in patients with renal cell carcinoma (RCC). The findings will be presented as part of the Poster Session: Renal Cell Cancer at the 2021 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU), which is being held virtually, February 11-13, 2021. All posters will be available on demand beginning at 5:00 a.m. PT on Thursday, February 11.
Global Rig ve Petrol Sahas? Minderleri Pazar Büyüklü?ü 2021 Sektöre Genel Bak??, Paylar, Büyüyen Talep, Gelirin Patlay?c? Faktörleri, Türler, Uygulamalar ve Industry Research Biz'den 2025 Tahmin Raporu – Haber Radikal haberradikal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from haberradikal.com Daily Mail and Mail on Sunday newspapers.